The research, led by Cassidy A. Guida of Wake Forest University School of Medicine, pooled individual participant data from seven randomized caloric restriction trials involving 829 older adults. The trials, drawn from Wake Forest’s Integrated Aging Studies Databank and Repository, ranged in duration from six to eighteen months and enrolled participants with overweight or obesity, many with coexisting conditions such as cardiovascular disease, knee osteoarthritis, or low physical function. Participants averaged 67.5 years of age, roughly two-thirds were women, and mean body mass index values ranged from about 30 to 36 kilograms per square meter across the contributing studies.

The biomarker index at the heart of the study was constructed following the framework of the TAME, or Targeting Aging with Metformin, Biomarkers Workgroup, which identified blood-based measures that best capture core hallmarks of aging while remaining practical for large clinical trials. Six biomarkers made the cut: C-reactive protein, interleukin-6, cystatin C, insulin, growth differentiation factor-15, and tumor necrosis factor-receptor 1. Together, these markers span inflammation, insulin signaling, metabolic stress, and renal function, domains that animal research has consistently tied to the biology of dietary restriction. Each participant’s change in each biomarker was converted to a quintile score, and the scores were summed into a single composite index, an approach intended to smooth out the inter-individual variability that plagues single-biomarker measures.

The results were strikingly consistent. Across the pooled trials, randomization to caloric restriction produced an average weight loss of 7.9 kilograms, compared with 1.2 kilograms in control groups, and was associated with a 2.2-point improvement in the composite biomarker quintile score, a statistically robust effect with every contributing study showing a benefit. Reductions were most pronounced in C-reactive protein, interleukin-6, insulin, and TNF-receptor 1, while cystatin C and GDF-15 showed more heterogeneity across studies. The consistency of the direction of effect, even in trials with different designs, intervention intensities, and follow-up periods, strengthens the case that the index is genuinely responsive to caloric restriction rather than an artifact of any single trial.

The most consequential question, however, was not whether caloric restriction improved the index, but how. Critics have long argued that the benefits of dietary restriction simply reflect weight loss itself rather than any special biology of eating less. To address this, the researchers performed a formal mediation analysis exploiting the randomization design: because assignment to caloric restriction was random, any relationship between the intervention and downstream outcomes could be decomposed into a portion mediated by weight loss and a residual, weight-independent effect.

The answer was nuanced. Roughly 48.5 percent of the effect of caloric restriction on the composite biomarker index was explained by the amount of weight participants lost. When change in body weight was added to the statistical model, the effect of caloric restriction shrank from minus 2.2 to minus 1.2 points, but it did not disappear. Conversely, the effect of weight loss itself dropped from 0.22 to 0.16 points per kilogram when caloric restriction assignment was accounted for. Both pathways, in other words, contribute independently. The residual direct effect of caloric restriction, at minus 1.34 points for the composite score, remained statistically significant, indicating that something beyond the number on the scale is driving the improvement.

That something may involve the nutrient-sensing pathways that decades of animal research have implicated in dietary restriction’s life-extending effects. Caloric restriction is known to activate AMP-activated protein kinase and sirtuin 1 while suppressing mechanistic target of rapamycin signaling, a trio of molecular switches that promotes autophagy, the cellular housekeeping that clears damaged proteins and organelles. These same pathways temper oxidative stress and chronic low-grade inflammation, providing a plausible biological bridge to the observed reductions in C-reactive protein and interleukin-6 that occurred independent of weight loss. Mitochondrial adaptations and shifts in innate immune cell metabolism may similarly underlie the insulin improvements seen in the trials, though the authors caution that these mechanisms were not directly measured and remain inferential.

The findings resonate with a broader pattern emerging across geroscience. In the landmark CALERIE trial, two years of roughly 12 percent caloric restriction in younger, normal-weight adults improved cardiometabolic risk factors and slowed the pace of aging as measured by the DunedinPACE epigenetic algorithm, yet did not change static estimates of biological age. Meanwhile, secondary analyses of the SELECT trial of semaglutide found that cardiovascular benefits persisted across weight categories and were driven in part by reductions in waist circumference rather than body weight alone. Together with the new pooled analysis, these results suggest that interventions targeting energy balance act through weight-dependent and weight-independent routes, and that responsive biomarker indices may capture these effects more faithfully than fixed biological age estimates.

The study has limitations worth noting. All seven trials came from a single research network with overlapping investigators and similar protocols, which may limit generalizability to more diverse populations. The intervention durations were relatively short, so the results demonstrate that caloric restriction favorably modifies aging-related biomarkers rather than proving reductions in disease or mortality. Individual components of the index, particularly GDF-15 and cystatin C, behaved inconsistently across studies, and whether the composite index correlates with epigenetic clocks or validated frailty measures remains an open question for future work.

Still, the implications are considerable. With roughly 40 percent of American adults aged 65 and older now living with obesity, and obesity a major driver of multimorbidity, frailty, and late-life disability, interventions that target the biology of aging hold enormous public health promise. The demonstration that a practical, six-marker blood index can detect intervention effects across heterogeneous trials positions such indices as potential surrogate endpoints for geroscience trials, potentially accelerating the testing of strategies to extend healthspan. And the finding that about half of caloric restriction’s benefit operates through pathways that weight loss alone cannot explain reinforces a message that biologists have been echoing from animal studies for decades: eating less does something to the machinery of aging that goes far beyond slimming down.

Subject of Research: The effect of caloric restriction on biological aging measured by a composite blood biomarker index in older adults

Article Title: Impact of caloric restriction on biological aging: insights from a composite biomarker index in older adults

Article References: Guida, C. A., Hsu, F.-C., Neiberg, R., Semelka, C., Chen, H., Kramer, P., Houston, D. K., Nicklas, B., Kritchevsky, S. B., & Miller, M. E. (2026). Impact of caloric restriction on biological aging: insights from a composite biomarker index in older adults. GeroScience. https://doi.org/10.1007/s11357-026-02529-9

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02529-9

Keywords: caloric restriction, biological aging, biomarkers, geroscience, older adults, inflammation, insulin, weight loss, mediation analysis, CRP, IL-6, Impact

Aging, an unavoidable biological phenomenon, is commonly linked to a surge in chronic ailments such as cancers, diabetes, and Alzheimer’s disease. Despite the extension of lifespan worldwide, the quality of these extended years often suffers due to the cumulative burden of these conditions. The visionary goal of Burkewitz’s laboratory is to decouple the aging process from the onset of disease, effectively prolonging healthy living rather than mere longevity. Their strategy delves deeply into the cell’s microcosm, focusing on how internal compartments, or organelles, organize and regulate metabolic and functional output.

At the heart of this exploration is the endoplasmic reticulum, an elaborate network of interconnected sheets and tubules that orchestrate a wide spectrum of cellular tasks including protein synthesis, lipid metabolism, and spatial organization of other organelles. Traditionally, aging research has concentrated on how the abundance and activity of cellular machineries fluctuate over time. However, the Burkewitz team shifts focus from quantity to spatial architecture, emphasizing the critical role of cellular organization in maintaining efficient metabolism and function during aging.

Using the nematode Caenorhabditis elegans as a model organism, the researchers have employed advanced genetic tools alongside state-of-the-art light and electron microscopy techniques. The transparency and rapid lifecycle of these worms provide a unique window into real-time changes within living cells throughout the aging process. The investigative team meticulously visualized dramatic alterations within the ER, observing that aging cells specifically reduce “rough” ER—responsible predominantly for protein production—while the “tubular” ER, associated with lipid synthesis, remains relatively stable. These structural changes resonate with the broader metabolic shifts characteristic of aging, such as declining proteostasis and altered lipid distribution.

Central to these observations is ER-phagy, a selective autophagic process that degrades specific subdomains of the ER. By targeting and removing dysfunctional segments, ER-phagy facilitates the remodeling of ER architecture in response to cellular stress and aging. The discovery that ER-phagy mediates such remodeling introduces a potentially modifiable pathway that directly influences lifespan and healthy aging, marking ER-phagy as a promising therapeutic target for intervening in age-related pathologies.

Eric Donahue, the paper’s first author and a medical scientist trainee, highlights the novelty of this discovery, emphasizing that the role of ER remodeling in aging was an unexplored facet of cellular biology. This work not only illuminates previously uncharted terrain in the aging puzzle but also underscores how early structural changes in cellular architecture might act as triggers for downstream dysfunction and disease manifestation.

Burkewitz’s analogy likens the cell to a factory where the organization of machinery dictates production efficiency and quality. As in a factory, the spatial arrangement within cells is paramount; even with all necessary components present, disorder results in operational failure. Likewise, ER remodeling functions like a factory retooling, optimizing its internal layout in response to shifting demands and constraints that arise during aging. Disruptions in ER organization correlate strongly with decreased cellular efficiency, metabolite imbalance, and ultimately, disease states.

The team’s findings also cast new light on the relationship between metabolic decline and organelle dynamics. The observed reduction in rough ER may underlie the deterioration of protein synthesis known to occur with age, while sustained tubular ER underlines an adaptive shift in lipid handling. These findings compel further investigation into how ER remodeling influences other organelles and systemic physiology, including the possible ripple effects on cellular signaling, energy balance, and homeostasis.

Going forward, the Burkewitz lab aims to dissect the molecular underpinnings of the ER’s structural plasticity and how this shape-shifting governs cell function across different tissue types. Given that ER architecture is a master regulator of numerous cellular compartments, unraveling its remodeling pathways might not only elucidate early biomarkers of aging but also reveal intervention points to stave off age-related deterioration.

Collaborative efforts with experts in cell biology, biochemistry, molecular physiology, and biophysics have enriched this research. The Vanderbilt teams, alongside partners from the University of Michigan and the University of California, San Diego, have collectively contributed advanced microscopy techniques and genetic approaches vital for capturing the minute architectural reorganizations occurring within living cells throughout aging.

Importantly, these revelations underscore the therapeutic potential of modulating ER-phagy. Pharmacological agents or genetic interventions designed to fine-tune this process could preserve ER integrity, thereby delaying or preventing the onset of chronic age-associated diseases. With aging populations worldwide expanding rapidly, such advances offer hope for healthier, more productive later years, reducing the personal and societal burdens imposed by aging-related chronic conditions.

In sum, the discovery that ER remodeling and ER-phagy are critically involved in aging charts a transformative shift in how we view cellular aging. From a static decline to a dynamic, organelle-driven process, this insight heralds new frontiers in aging research and drug development. As science progressively unravels these intricate cellular narratives, the prospect of enhancing healthspan alongside lifespan becomes ever more tangible.

Subject of Research: Cellular remodeling in aging; endoplasmic reticulum; ER-phagy; aging biology; cellular architecture
Article Title: ER remodeling is a feature of aging and depends on ER-phagy
News Publication Date: 2-Feb-2026
Image Credits: Burkewitz et. al.
Keywords: Endoplasmic reticulum, Aging populations, Electron microscopy

Rapamycin, a well-characterized mTOR (mechanistic target of rapamycin) inhibitor, has long been recognized for its powerful geroprotective properties across multiple animal models. By suppressing mTOR signaling, Rapamycin effectively slows metabolic activity associated with ageing, reduces cellular senescence, and bolsters autophagy, thereby enhancing tissue maintenance and longevity. On the other hand, Trametinib operates through selective inhibition of MEK1 and MEK2 kinases within the Ras/MEK/ERK signaling axis, a critical pathway implicated in cell proliferation and survival. While previously demonstrated to extend lifespan in model organisms such as Drosophila, Trametinib’s geroprotective effects in mammals had not been established until now.

In this comprehensive experimental study, researchers administered these drugs individually and in combination to laboratory mice, meticulously monitoring their health parameters and survival outcomes over time. Notably, Trametinib alone extended median lifespan by approximately 5 to 10 percent, whereas Rapamycin alone yielded a 15 to 20 percent increase. Strikingly, the dual therapy boosted lifespan by around 30 percent, indicating an additive or potentially synergistic interaction that elevates the efficacy of geroprotection beyond simple dose escalation.

Beyond longevity, the intervention demonstrated significant improvements in health metrics associated with ageing. Chronically inflamed tissues—a hallmark of ageing—showed markedly reduced inflammatory markers following combination treatment. This attenuation of systemic inflammation was apparent not only in peripheral organs but also within the central nervous system, suggesting neuroprotective benefits. Moreover, the onset and progression of spontaneous cancers, a major cause of morbidity and mortality in aged mice, were notably delayed, providing additional evidence that this therapeutic strategy can forestall common age-related pathologies.

At the molecular level, the study revealed intriguing mechanistic insights into how these compounds interact to modulate ageing networks. Rapamycin and Trametinib target intersecting nodes within the Ras/Insulin/TOR signaling nexus, which orchestrates cellular growth, metabolism, and stress responses. Crucially, gene expression analysis across various tissues demonstrated that the combination therapy produces unique transcriptional changes not merely attributable to increased drug dosage or additive effects. These distinct gene regulation patterns hint at emergent biological phenomena arising from simultaneous modulation of multiple signaling cascades involved in lifespan regulation.

This discovery challenges conventional perspectives that evaluate geroprotective agents solely based on their individual efficacies. Instead, it underscores the potential of rational polypharmacy—strategically combining drugs affecting complementary pathways—to amplify health and longevity benefits. The lack of additional adverse side effects in the combination group further encourages the translational potential of this approach.

Given that Trametinib is already clinically approved for oncological applications, the progression from preclinical mouse studies to human trials could be relatively expeditious. Nonetheless, optimizing dosage regimens and administration routes remains paramount to maximize benefits while minimizing toxicity. Future research will focus on refining these parameters and verifying efficacy in diverse mammalian models to pave the way for clinical geroprotector development.

Senior researchers emphasize cautious optimism; while the extraordinary 30 percent lifespan extension observed in mice may not directly extrapolate to humans, the fundamental mechanisms targeted are conserved. The overarching goal is to extend the duration of healthy life, delaying the onset of chronic diseases and maintaining function in later years rather than merely increasing total lifespan.

This study also exemplifies the growing recognition that targeting ageing processes systemically can yield multi-organsystem benefits, fundamentally different from conventional therapies aimed at individual diseases. By attenuating chronic inflammation, modulating metabolism, and delaying oncogenesis simultaneously, such interventions could profoundly reshape preventive medicine and geriatric care.

Moreover, the identification of specific gene expression signatures unique to the combined therapy opens new research pathways to explore biomarkers predicting treatment responsiveness and to dissect the complex molecular interplay underpinning ageing modulation.

The research, published in Nature Aging, represents a landmark contribution to longevity science underpinned by rigorous experimental design and comprehensive molecular evaluation. Funding from the European Research Council and collaboration with the CECAD Cluster of Excellence at the University of Cologne highlights the strong interdisciplinary and international commitment to advancing understanding of ageing biology.

As the scientific community eagerly awaits clinical translation, this discovery propels excitement about the feasibility of targeting conserved signaling networks pharmacologically to enhance life quality and length. It exemplifies how re-purposing and combining existing drugs can yield unexpected and transformative benefits, accelerating the journey toward effective age-combatting therapies.

In conclusion, the synergistic use of Rapamycin and Trametinib heralds a new horizon for geroprotection, establishing that simultaneously modulating distinct but interconnected pathways involved in ageing can lead to unprecedented improvements in healthspan and survival. This pivotal study deepens our grasp of molecular ageing processes and charts a promising course toward clinically applicable interventions that may one day allow humans to enjoy longer, healthier lives, free from the burden of age-related decline.

Subject of Research: Animals
Article Title: The geroprotectors Trametinib and Rapamycin combine additively to extend mouse healthspan and lifespan
News Publication Date: 28-May-2025
Web References: http://dx.doi.org/10.1038/s43587-025-00876-4
Image Credits: K. Link / Max Planck Institute for Biology of Ageing
Keywords: Rapamycin, Trametinib, Geroprotector, Lifespan Extension, Healthspan, Chronic Inflammation, Cancer Delay, Ras/Insulin/TOR Network, MEK Inhibition, Ageing, mTOR Pathway, Polypharmacy